Abstract
Background Being unable to suppress SARS-CoV-2 transmission, the majority of countries worldwide have resorted to a mitigation approach, adjusting physical distancing restrictions (PDRs) to find a balance between viral circulation, individual freedoms and economic losses. Vaccination campaigns in many countries are allowing the progressive release of restrictions aimed at reducing infectious contacts.
Methods We propose a novel mathematical modeling framework where we assume that PDRs are adjusted to maintain an approximately constant incidence, allowing for a progressive resuming of contacts as population immunity accrues. Different scenarios are investigated to evaluate the impact on reopening of critical vaccination parameters, such as the number of daily doses administered, the coverage, the duration of vaccine protection.
Results We identify five conditions that can allow the complete resuming of pre-pandemic contacts within 9 to 15 months since vaccination start: a sufficiently high coverage (around 75%) and capacity (around 4 daily doses per 1,000 population), a high vaccine efficacy on preventing infections, the availability of a pediatric vaccine, and a long-term duration of protection. If these conditions are met, the two-year cumulative incidence of deaths is expected to remain between 0.43 and 0.77 per 1,000 population. A short-lived vaccine protection will require re-vaccination campaigns, in absence of which a new intensification of PDRs is expected around month 14. Strategies oriented to prioritize the suppression of SARS-CoV-2 by maintaining strict restrictions will not be able to reduce the time to complete reopening, possibly resulting in acceptability issues; on the other hand, we caution that a premature reopening after the vaccination of the most fragile population segments may result in large epidemics with a heavy burden of deaths.
Conclusions Vaccination programs can allow a return to normal under the identified conditions, but the release of PDRs must be gradual to avoid new epidemic waves and unnecessary deaths.
Competing Interest Statement
M.A. has received research funding from Seqirus. The funding is not related to COVID-19. All other authors declare no competing interest.
Funding Statement
V.M., G.G., P.Po., F.T., M.M. and S.M. acknowledge funding from EU grant 874850 MOOD (catalogued as MOOD 000). The contents of this publication are the sole responsibility of the authors and don't necessarily reflect the views of the funders.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No IRB was needed for this study
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Data Availability
Data used in the manuscript are publicly available.
